 |
|
Antibody Concentration and Clinical Protection After Hib Conjugate Vaccination in the United Kingdom
Paul T. Heath, FRACP;
Robert Booy, FRACP;
Helen J. Azzopardi, FIBMS;
Mary P. E. Slack, FRCPath;
Jane Bowen-Morris, BSc;
Helen Griffiths, FRCPath;
Mary E. Ramsay, MFPHM;
Jon J. Deeks, MSc;
E. Richard Moxon, FRCP
JAMA. 2000;284:2334-2340.
Context The schedule for Haemophilus influenzae type b (Hib) vaccination of infants in the United Kingdom consists of 3 doses given at 2, 3, and 4 months of age. Many countries include a fourth dose (booster) of Hib vaccine in the second year of life on the basis of declining Hib antibody concentrations after the primary series. Few data are available to show that this fourth dose is actually necessary.
Objective To evaluate long-term clinical protection against Hib disease and Hib antibody concentrations following primary Hib vaccination without a booster dose.
Design, Setting, and Subjects Clinical protection study conducted between October 1992 and March 1999 in the United Kingdom, in which children developing invasive Hib disease despite vaccination in infancy with 3 doses of Hib conjugate vaccine were reported by pediatricians through an active, prospective, national survey. Separate antibody studies were conducted among 2 cohorts of children (n = 153 and n = 107) vaccinated at 2, 3, and 4 months of age with Hib conjugate vaccine and followed up to 43 and 72 months of age.
Main Outcome Measures Age-specific vaccine effectiveness, derived from the observed number of true vaccine failures after 3 Hib vaccine doses compared with the number of cases expected based on the age-specific rates of invasive Hib disease obtained prior to the introduction of Hib vaccines; and proportion of children in the 2 cohorts with Hib antibody concentrations of less than 0.15 and less than 1.0 µg/mL.
Results Ninety-six true vaccine failures occurring after 3 vaccine doses were detected. During the study period, an estimated 4,368,200 infants in the United Kingdom received 3 doses of vaccine; therefore, the vaccine failure rate was 2.2 per 100,000 vaccinees (95% confidence interval, 1.8-2.7 per 100,000). Although vaccine effectiveness declined significantly after the first year of life (P<.001), it remained high until the sixth year of life (99.4% in children aged 5-11 months vs 97.3% in those aged 12-71 months). The proportion of cohorts 1 and 2 with anti-PRP antibody levels of less than 0.15 µg/mL increased between 12 and 72 months of age (6% at 12 months, 8% at 43 months, and 32% at 72 months;  21 = 18.25; P<.001 for trend).
Conclusions Our results suggest that anti-PRP antibody levels and clinical protection against Hib disease wane over time after Hib vaccination at 2, 3, and 4 months of age without a booster dose at 2 years of age. The decline in clinical protection is minimal, however, suggesting that a booster dose of Hib vaccine following infant vaccination is not essential.
Author Affiliations: Oxford Vaccine Group (Drs Heath and Griffiths, Mrs Bowen-Morris, and Professor Moxon) and the Public Health Laboratory Service Haemophilus Reference Laboratory (Ms Azzopardi and Dr Slack), John Radcliffe Hospital, Oxford, England; Department of Child Health, St Bartholomew's and the Royal London School of Medicine and Dentistry, London, England (Professor Booy); Public Health Laboratory Service Communicable Disease Surveillance Centre, Colindale, London (Dr Ramsay); and the Centre for Statistics in Medicine, Institute of Health Sciences, Oxford (Mr Deeks). Dr Heath is now with the Department of Child Health and St George's Vaccine Institute, St George's Hospital Medical School, London, England.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLE
November 8, 2000
JAMA. 2000;284(18):2393-2394.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Anti-Polyribosylribitol Phosphate Antibody Concentrations and Avidities in Children since the Start of Haemophilus influenzae Type b Immunization of Infants in the United Kingdom
Kelly et al.
CVI 2009;16:246-252.
ABSTRACT
| FULL TEXT
A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial
Pace et al.
Arch. Dis. Child. 2008;93:963-970.
ABSTRACT
| FULL TEXT
Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign
Ladhani et al.
Arch. Dis. Child. 2008;93:665-669.
ABSTRACT
| FULL TEXT
EMQ answers
Emerg. Med. J. 2008;25:316-316.
FULL TEXT
Quality of the Haemophilus influenzae Type b (Hib) Antibody Response Induced by Diphtheria-Tetanus-Acellular Pertussis/Hib Combination Vaccines
Denoel et al.
CVI 2007;14:1362-1369.
ABSTRACT
| FULL TEXT
Immunologic Response to Haemophilus influenzae Type b (Hib) Conjugate Vaccine and Risk Factors for Carriage among Hib Carriers and Noncarriers in Southwestern Alaska
Baggett et al.
CVI 2006;13:620-626.
ABSTRACT
| FULL TEXT
Immunological Memory: The Role of B Cells in Long-term Protection Against Invasive Bacterial Pathogens
Kelly et al.
JAMA 2005;294:3019-3023.
ABSTRACT
| FULL TEXT
Conjugate vaccines
Finn and Heath
Arch. Dis. Child. 2005;90:667-669.
FULL TEXT
Immunogenicity and Safety of a Combination Pneumococcal-Meningococcal Vaccine in Infants: A Randomized Controlled Trial
Buttery et al.
JAMA 2005;293:1751-1758.
ABSTRACT
| FULL TEXT
Obstacles to the Elimination of Haemophilus influenzae Type b Disease: Three Illustrative Cases
Donnelly et al.
Pediatrics 2003;112:1465-1466.
FULL TEXT
Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure
McVernon et al.
Arch. Dis. Child. 2003;88:379-383.
ABSTRACT
| FULL TEXT
Pneumococcal Vaccination and Revaccination of Older Adults
Artz et al.
Clin. Microbiol. Rev. 2003;16:308-318.
ABSTRACT
| FULL TEXT
Hib vaccination in infants born prematurely
Heath et al.
Arch. Dis. Child. 2003;88:206-210.
ABSTRACT
| FULL TEXT
Haemophilus influenzae type b epiglottitis. Article gives timely lesson.
Lee et al.
BMJ 2003;326:284-284.
FULL TEXT
Effect of a fourth Haemophilus influenzae type b immunisation in preterm infants who received dexamethasone for chronic lung disease
Clarke et al.
Arch. Dis. Child. Fetal Neonatal Ed. 2003;88:F58-61.
ABSTRACT
| FULL TEXT
Lesson of the week: Haemophilus influenzae type b epiglottitis as a cause of acute upper airways obstruction in children
Tanner et al.
BMJ 2002;325:1099-1100.
FULL TEXT
Development and Validation of a Multivariable Predictive Model to Distinguish Bacterial From Aseptic Meningitis in Children in the Post-Haemophilus influenzae Era
Nigrovic et al.
Pediatrics 2002;110:712-719.
ABSTRACT
| FULL TEXT
The UK Hib vaccine experience
Heath and McVernon
Arch. Dis. Child. 2002;86:396-399.
ABSTRACT
| FULL TEXT
Capsulate bacteria and the lung: Childhood respiratory infections
Buttery and Moxon
Br Med Bull 2002;61:63-80.
ABSTRACT
| FULL TEXT
Legacy of bacterial meningitis in infancy
Grimwood
BMJ 2001;323:523-524.
FULL TEXT
Haemophilus influenzae Vaccine: Three or Four Doses?
JWatch Infect. Diseases 2000;2000:12-12.
FULL TEXT
|
